ArticleCPT: pharmacometrics & systems pharmacology2026
Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age-Related Fluoxetine Accumulation in the Elderly.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study quantified age-related differences in fluoxetine pharmacokinetics and evaluated the influence of CYP2D6 phenotype using physiologically based pharmacokinetic (PBPK) modeling integrated with clinical therapeutic drug monitoring data. A PBPK model for fluoxetine and its active metabolite norfluoxetine was implemented in the Simcyp Simulator and verified using published pharmacokinetic studies. Simulations of repeated fluoxetine administration (20 mg once daily) were performed in younger adults (18-65 years) and elderly individuals (65-98 years). Model predictions were compared with therapeutic drug monitoring data from Korean 47 patients (18-88 years) receiving fluoxetine for at least 5 weeks. Simulations demonstrated delayed steady-state attainment and reduced clearance in elderly individuals, resulting in approximately two-fold higher fluoxetine exposure after prolonged dosing and 1.5-fold higher total active moiety exposure than in younger adults. Clinical observations supported these findings, with significantly higher dose-normalized trough concentrations in elderly patients. Although CYP2D6 phenotype affected parent-drug exposure, total active moiety exposure varied only modestly across phenotypes, suggesting that CYP2D6 phenotyping may not be necessary when titrating fluoxetine doses in elderly patients. These findings demonstrate that aging may enhance fluoxetine accumulation during chronic therapy, supporting cautious dose titration and extended monitoring in the elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.